Literature DB >> 31738733

Rare bleeding disorders and advances in gene therapy.

Tian Liu1, Zhigang Yang2.   

Abstract

: Rare bleeding disorders usually begin in childhood and manifest as varying degrees of bleeding, which can be life-threatening in severe cases. With the development of gene editing technology, it is expected that hereditary coagulation factor disorders will someday be fundamentally cured by gene therapy. On account of their rarity, comprehension of these diseases is essential for the application of new treatment strategies. We have compiled the features of some newly discovered mutations of prothrombin, factor VII, and factor X in recent years. In addition, this review introduces the advances and obstacles in gene therapy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31738733     DOI: 10.1097/MBC.0000000000000852

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  Treatment of patients with rare bleeding disorders in the Netherlands: Real-life data from the RBiN study.

Authors:  Dominique P M S M Maas; Joline L Saes; Nicole M A Blijlevens; Marjon H Cnossen; Paul L den Exter; Ilmar C Kruis; Karina Meijer; Laurens Nieuwenhuizen; Marjolein Peters; Roger E G Schutgens; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2022-02-08       Impact factor: 16.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.